Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 12/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 8/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 6/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 0.60 |
| ▸ | RXRB | P28702 | 1/20 | 0.60 |
| ▸ | RXRG | P48443 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4338759 | 0.89 | HDAC1 (1.00) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL3045891 | 0.87 | HDAC1 (0.76) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL4327548 | 0.87 | HDAC1 (0.76) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL3054236 | 0.84 | HDAC1 (0.72) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL15606558 | 0.82 | HDAC1 (0.70) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL10247700 | 0.81 | RXRA (0.78) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL4335149 | 0.79 | HDAC1 (0.65) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL14624038 | 0.79 | HDAC1 (0.65) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL10247702 | 0.78 | HDAC1 (0.64) | HDAC1HDAC2HDAC6HDAC8HDAC3 | |
| SCHEMBL4329559 | 0.78 | HDAC1 (0.77) | HDAC1HDAC2HDAC6HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-09-06 | — | — | US | claimed |
| EP-1787986-A1 | HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-05-23 | — | — | EP | claimed |
| US-7521563-B2 | Hydroxamic acid derivative and medicine containing the same as active ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1787986-A1 | HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | IL6, IL1A, TNF | HDAC1 27/4885HDAC2 69/4885HDAC6 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.